Friday, May 1, 2026

Can Atherosclerosis Be Reversed? A Deep, Candid Dive Into Artery Health

 


For years, the phrase “hardening of the arteries” scared the life out of patients and doctors alike. Atherosclerosis—the silent, steady build-up of plaque inside your arteries—was seen as a one-way street to heart attacks, strokes, and a lifetime of pills. But as research has gotten more sophisticated, the conversation has shifted. People want to know: can atherosclerosis be reversed, or is it just wishful thinking?

This is your no-nonsense, evidence-backed, and brutally honest deep dive into the science, the hope, and the hype surrounding the reversal of atherosclerosis.


What Exactly Is Atherosclerosis?

Atherosclerosis starts with irritation or damage to the inner lining of your arteries. High blood pressure, smoking, high blood sugar, and especially LDL (“bad”) cholesterol all contribute. Over years—or even decades—tiny injuries invite cholesterol, fats, calcium, and immune cells to pile up under the artery lining. The result: a plaque that narrows and stiffens the artery, forming a kind of biological “scar tissue” that can grow, rupture, or calcify (Mayo Clinic).

The scariest part? Most people have no symptoms until a plaque ruptures or blocks off blood flow—meaning the first sign could be a heart attack or stroke.


The Old View: Once Clogged, Always Clogged?

For decades, textbooks said atherosclerosis was irreversible. Doctors focused on slowing the progression—controlling cholesterol, blood pressure, and blood sugar; encouraging people to quit smoking; and getting them moving.

By the 1980s, angioplasty and bypass surgery could “detour” around blocked arteries, but didn’t clear out the plaque itself. The consensus: you could stabilize the problem, but you couldn’t fix it.


The New Evidence: Can Plaque Actually Shrink?

Here’s where things get interesting.

Medications That Do More Than Slow the Disease

Statins Take Center Stage

Statins (like atorvastatin, rosuvastatin) were game-changers. They lower LDL cholesterol, reduce inflammation, and have been shown to decrease heart attacks and strokes. But could they reverse plaque?

The ASTEROID trial in 2006 was a bombshell. Using high-dose rosuvastatin, researchers saw a measurable—though modest—reduction in plaque volume inside coronary arteries, as visualized by intravascular ultrasound. Not enough to “unclog” arteries entirely, but enough to prove that plaque regression was possible (NEJM).

Other studies have backed this up: statins, especially when LDL is driven very low (under 70 mg/dL), reduce the fatty, “soft” component of plaque, making it less likely to rupture.

PCSK9 Inhibitors: The New Kids on the Block

Drugs like evolocumab and alirocumab can drop LDL to previously unheard-of levels. Early studies show adding these to statins can shrink plaque volume even further, though (again) the change is modest (JAMA).

Anti-Inflammatory Drugs

The CANTOS trial tested canakinumab, targeting inflammation without touching cholesterol. The results: fewer heart attacks, fewer strokes, and a suggestion that “quieting” inflammation also stabilizes dangerous plaques (NEJM). Still, these drugs are costly and not for everyone.


Lifestyle Change: The Ornish and Esselstyn Protocols

The Ornish Study

Dr. Dean Ornish’s research in the 1990s turned cardiology on its ear. He put patients with heart disease on a strict, plant-based diet (less than 10% of calories from fat), coupled with moderate exercise, stress management, and group support. Over a year, angiograms showed slight regression of plaque in the treatment group, while the control group worsened (Lancet). At five years, the difference persisted—but only for those who stuck to the program.

Caldwell Esselstyn’s Cleveland Clinic Experience

Dr. Esselstyn’s patients followed an even stricter plant-based, oil-free diet. Many saw their angina vanish and, in some cases, had reversal of blockages on follow-up imaging (Cleveland Clinic).

Real Talk About Lifestyle Interventions

These changes are drastic. Very few people stick to them long-term. But for those who do, the results are remarkable—reduced symptoms, fewer procedures, and, in select cases, actual plaque regression.


What About Supplements and “Natural” Cures?

  • Niacin: Once hailed as a wonder drug for raising HDL, large trials have shown no benefit and plenty of side effects.
  • Fish Oil: Modest benefit in high-risk people, but not a plaque-melting miracle.
  • Chelation Therapy, Cleanses, “Artery Flushes”: Chelation therapy with EDTA has shown some credibility. I've personally talked with many patients who swear by EDTA chelation while I myself was being chelated. People who couldn't walk to their mail boxes to get the mail were again playing golf after being chelated. Cleanses and artery flushes show No credible evidence, and some are downright dangerous. Steer clear.
  • Nattokinase: Yes, evidence suggests that high-dose nattokinase (around 10,800 FU/day) can significantly reduce and potentially reverse plaque buildup in arteries, with studies showing reductions in carotid plaque size by up to 36% or more over 12 months. It works by decreasing carotid intima-media thickness, managing atherosclerosis, lowering lipids, and providing fibrinolytic, anti-inflammatory, and anti-atherosclerotic effects. More on Nattokinase

What Does “Reversal” Actually Mean?

Here’s the catch: most plaque regression is mild. We’re talking millimeters—enough to lower risk, not enough to turn a 70-year-old’s arteries back into a teenager’s. More often, the goal is stabilization—making plaques less likely to rupture, even if they don’t shrink dramatically.

But in the world of heart disease, stabilization IS a kind of reversal. If you can lower your risk of a heart attack, live longer, and feel better, that’s a win.


The Numbers: What Can You Really Expect?

  • Statins: 0–2% reduction in plaque volume per year in aggressive therapy groups.
  • PCSK9 inhibitors + statins: Up to 1% additional reduction.
  • Ornish/Esselstyn lifestyle: 2–8% regression in select motivated patients, especially if started early and followed strictly.
  • Most people: Significant risk reduction, even if the arteries themselves don’t look much different on scans.

Who Should Aim For Reversal?

  • High-risk patients: Those with known heart disease, diabetes, or multiple risk factors benefit the most.
  • Highly motivated individuals: Willing to make major lifestyle changes, under medical supervision.
  • Early/intermediate disease: The earlier you start, the better your odds.

The Bottom Line: Can You Reverse Atherosclerosis?

Yes, but with caveats. True, complete reversal is rare. But you can shrink plaques a bit, stabilize them a lot, and dramatically cut your risk with a combination of medication and lifestyle overhaul.

Don’t buy into miracle cures or quick fixes. The science says real progress is possible—with consistent effort, medical oversight, and, frankly, some stubbornness.


Credits


Final Word

If you’re staring down a diagnosis of atherosclerosis, don’t panic—but don’t settle, either. You can tilt the odds in your favor, sometimes even nudge those plaques backward, if you’re willing to do the work. And even if you can’t get rid of every last bit of plaque, you can almost always make your arteries—and your future—a whole lot safer.

Check out Nattokinase

Does High Dose Nattokinase Reduce Arterial Plaque? A Deep Dive Into the Evidence

 

nattokinase reduces arterial plaque

Nattokinase, an enzyme extracted from the traditional Japanese fermented soybean dish natto, has gained attention as a natural supplement with potential cardiovascular benefits. Among the claims, one of the most intriguing is its ability to reduce arterial plaque—a central factor in atherosclerosis and cardiovascular disease. But does high-dose nattokinase truly shrink arterial plaque, or is this another overhyped supplement?

This deep dive examines the latest clinical studies, mechanisms of action, safety considerations, and what the science really says about nattokinase’s role in managing arterial plaque.


Understanding Arterial Plaque and Atherosclerosis

Atherosclerosis is a chronic condition characterized by the build-up of fatty plaques in arterial walls. These plaques narrow the arteries, reduce blood flow, and can lead to heart attacks and strokes. Reducing or stabilizing plaque is a key goal in cardiovascular health.


What Is Nattokinase?

Nattokinase is a fibrinolytic enzyme, meaning it can break down fibrin, a protein involved in blood clotting. Derived from natto, nattokinase has been studied for its blood-thinning, antithrombotic, and potential anti-atherosclerotic effects.


Clinical Evidence: Does High Dose Nattokinase Reduce Plaque?

Large-Scale Clinical Study with Over 1,000 Participants

A 2022 clinical study involving 1,062 participants investigated nattokinase’s effects on atherosclerosis progression and hyperlipidemia. Participants received a high dose of nattokinase—around 10,800 fibrinolytic units (FU) daily, which is notably higher than typical doses.

Findings:

  • Significant reduction in carotid artery plaque size.
  • Improvement in lipid profiles (lower LDL cholesterol and triglycerides).
  • Decreased carotid intima-media thickness (a marker of arterial wall thickening).
  • Comparable anti-atherosclerotic effects to aspirin, as nattokinase shares similar pathways in preventing platelet aggregation and inflammation.

This study suggests that high-dose nattokinase can effectively slow progression and even reduce arterial plaque burden in patients with existing atherosclerosis (Frontiers in Cardiovascular Medicine, 2022).

Meta-Analysis of Randomized Controlled Trials

A 2023 meta-analysis reviewing multiple randomized trials found that administration of high-dose nattokinase (around 6,500 FU daily for 26 weeks or longer) was effective in inhibiting the progression of atherosclerotic plaques and improving cardiovascular risk factors, including blood pressure and lipid levels (PMC, 2023).

Other Clinical Findings

  • Reduction in common carotid artery intima-media thickness (CCA-IMT), a surrogate marker for atherosclerosis.
  • Improvement in endothelial function, which helps arteries dilate and maintain healthy blood flow.
  • Lipid-lowering effects contributing to plaque stabilization (Sage Journals, 2018).

How Does Nattokinase Work Against Arterial Plaque?

Fibrinolytic and Antithrombotic Effects

Nattokinase promotes the breakdown of fibrin, which not only helps dissolve blood clots but may also contribute to degrading fibrin-rich components of arterial plaques, potentially shrinking soft plaques and preventing new clot formation.

Anti-Inflammatory and Antioxidant Properties

Chronic inflammation drives plaque formation and instability. Nattokinase has been shown to reduce inflammatory markers and oxidative stress, which could slow plaque progression and stabilize existing plaques.

Gene Regulation and Cellular Effects

Recent research suggests nattokinase upregulates genes related to autophagy (cellular cleanup processes) and reduces necroptosis (a form of programmed cell death linked to inflammation), further protecting vascular health (ScienceDirect).


Safety and Dosage of High-Dose Nattokinase

Typical and High Doses

  • Common doses range from 2,000 to 4,000 FU daily.
  • High doses used in clinical studies are around 6,500 to 10,800 FU daily.

Safety Profile

  • Generally considered safe when taken orally for up to 3 years.
  • Potential bleeding risk exists, especially when combined with other anticoagulants or in patients with bleeding disorders.
  • Monitoring is advised for those on blood thinners or with surgery planned (WebMD, Examine.com).

Practical Considerations

  • Consult your healthcare provider before starting nattokinase, especially if you are on blood thinners or have bleeding risks.
  • High doses have shown promising results but require careful monitoring.
  • Nattokinase can be a complementary approach, but it should not replace conventional therapies for atherosclerosis.

Summary

  • High-dose nattokinase (6,500 to 10,800 FU daily) has demonstrated potential to reduce arterial plaque size and improve cardiovascular risk markers in clinical studies.
  • Its mechanisms include fibrinolytic activity, anti-inflammatory effects, and gene-level modulation protecting vascular cells.
  • Safety is generally acceptable at studied doses, but bleeding risk should be considered.
  • More large-scale, long-term studies are needed to fully establish nattokinase’s role in clinical practice.

References and Credits

  • Chen H, Chen J, Zhang F, Li Y, Wang R. "Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants." Frontiers in Cardiovascular Medicine, 2022. Link
  • Li X, Long J, Gao Q, Pan M, Wang J, et al. "Nattokinase supplementation and cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials." PMC, 2023. Link
  • Chen H, McGowan EM, Ren N, Lal S, et al. "Nattokinase: a promising alternative in prevention and treatment of cardiovascular diseases." Biomarker Insights, 2018. Link
  • Liu M, Xu Z, Wang Z, Wang D, Yang M, Li H, et al. "Lipid-lowering, antihypertensive, and antithrombotic effects of nattokinase combined with red yeast rice in patients with stable coronary artery disease: a randomized, double-blind trial." Frontiers in Nutrition, 2024. Link
  • WebMD, Nattokinase Safety and Use. Link
  • Examine.com, Nattokinase Supplement Review. Link

In conclusion, high-dose nattokinase shows promising evidence for reducing arterial plaque and improving cardiovascular health markers, but it’s no magic bullet. It’s best seen as part of an integrative approach alongside lifestyle changes and conventional therapies, under medical supervision.